Phibro Animal Health posts transcript of Q4 2026 earnings call

PUBT · 20h ago
Phibro Animal Health posts transcript of Q4 2026 earnings call
  • Phibro Animal Health published its fiscal Q4 2026 earnings-call transcript; attendees included the CEO, CFO, COO, operators, analysts.
  • FY2027 outlook: net sales USD 1.55-1.6 billion, adjusted EBITDA USD 258-268 million, adjusted diluted EPS USD 3.41-3.59.
  • Planning assumes minimal virginiamycin sales in Brazil; FY2026 Brazil virginiamycin sales were about USD 27 million, creating downside to margins.
  • Planned closure of Chicago Heights manufacturing site; annual adjusted EBITDA benefit estimated at USD 15-20 million, mostly from FY2028.
  • FY2026 results: net sales USD 1.52 billion; adjusted EBITDA USD 255 million; free cash flow USD 10 million on USD 86.3 million inventory build.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.